To accelerate momentum in the global fight against hepatitis B, expanding testing and treatment services in resource-limited countries is crucial, especially in sub-Saharan Africa. But determining which patients are eligible for treatment is a complex process and requires tests that are not widely accessible in these regions. Should all people infected with the virus be treated without assessing their eligibility for treatment (a "Treat All" strategy)? Using a mathematical model, scientists determined that an alternative combining simple diagnostic tests is cost-effective and sufficiently effective in assessing whether a patient should receive treatment.

Find out more